Please Wait.....
Report
Monoclonal Antibodies for Oncology: Global Markets
Market Research Report I 2022-06-15 I 124 Pages I BCC Research
Description
Report Scope:
The current report provides detailed exposure of global monoclonal antibodies for the oncology market. This report highlights the current and future market potential of monoclonal antibodies for oncology treatment and includes a detailed analysis of the market's drivers, challenges, and opportunities. The report also covers market projections to 2027 and market share for key market players. The report details the market share of monoclonal antibodies for oncology based on type and application. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides the impact of the COVID-19 pandemic on this market.
Report Includes:
- 25 data tables and 24 additional tables
- A brief general outlook of the global monoclonal antibodies for oncology market
- Analyses of the global market trends, with market revenue (sales data) for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the current and future market potential of monoclonal antibodies for oncology treatment, and areas of focus to forecast this market into various segments and sub-segments
- Evaluation of the actual market size for monoclonal antibodies in oncology treatment, forecasted growth trends, and corresponding market share analysis by type of antibody, application area, and region
- Technology assessment of the key drivers, restraints and opportunities that will shape the market over the next five years (2022 to 2027)
- In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, major types of end-user markets, and COVID-19 implications on the progress of this market
- Review of the patent landscape and new developments in the market for monoclonal antibodies for oncology and associated clinical trials
- Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
- Company profiles of major players, including AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc, Pfizer Inc.
Executive Summary
Summary:
Monoclonal antibody drugs are created through the use of modern scientific techniques such as genetic engineering and recombinant deoxyribonucleic acid (DNA) technology. They are produced by living cells and organisms such as Escherichia coli (E. coli), yeast, mammalian cells, etc. These drugs have gained a lot of interest in the field of oncology. Monoclonal antibodies are considered to be an effective treatment option for cancer compared to conventional treatment such as chemotherapy, which is associated with severe adverse effects. Over the past REDACTED, years, different forms of monoclonal antibodies derived treatments have been used to capitalize on the potential of targeted therapy. After the discovery of the first monoclonal antibody for oncology in 1997, there are number of others that have received approvals for various forms of cancer. Monoclonal antibodies are a form of targeted therapy and are also employed in other ways for cancer treatments such as antibody-drug conjugates, targeting pro-tumorigenic compounds in the microenvironment, bispecific T cell engagers (BiTEs), and immune checkpoint inhibitors. Notably, the highest-selling drug in the oncology market is an immune checkpoint inhibitor, Keytruda (pembrolizumab), from Merck & Co., with reported sales of $REDACTED, in 2021.
The demand for monoclonal antibodies for oncology treatment is driven by the increasing prevalence of cancer worldwide. According to GLOBOCAN, there were REDACTED, new cases of cancer worldwide in REDACTED, and this figure is forecast to reach REDACTED, cases by REDACTED,. According to WHO, breast cancer, lung cancer, and colorectal cancer had the highest number of new cases in REDACTED,. The growing prevalence of cancer and the demand for effective and less-toxic treatments is contributing to the growth of the market. Advanced diagnostic and awareness campaigns facilitate an increasing number of cancer cases being diagnosed at early stages. Advancements in biomarkers play a vital role in the detection of cancers at early stages, which leads to improved survival rates and increased treatment duration leading to the growth of the market. The oncology market will therefore witness growing demand for monoclonal antibodies due to the increased adoption of biological drugs.
The global market for monoclonal antibodies for oncology is valued at $REDACTED, in 2021 and is forecast to grow at a compound annual growth rate (CAGR) of REDACTED,% to reach $REDACTED, in 2027. The major players in the market are F. Hoffman La Roche, Merck & Co., Bristol Myers Squibb, J&J, Amgen, and AstraZeneca.
In this report, the market is segmented based on type, application, and region. Based on the type, the market is segmented as humanized, human, and chimeric monoclonal antibodies. Humanized monoclonal antibodies had the highest share in the monoclonal antibodies oncology market and includes drugs such as Keytruda (Pembrolizumab), Tecentriq (Atezolizumab), and Perjeta (pertuzumab). Human antibodies also have blockbuster drugs such as Opdivo (nivolumab), Yervoy (ipilimumab), Darzalex (Daratumumab), and Xgeva (Denosumab). Based on application, the market is segmented into lung cancer, breast cancer, blood cancer, colorectal cancer, and other cancers. Based on region, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The North American market had the highest share, followed by Europe. This leadership role is due to increasing prevalence, rising awareness, early diagnosis, the presence of major players, government initiatives, funding, and good healthcare infrastructure.
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Monoclonal Antibodies
History of Monoclonal Antibodies
Advantages and Disadvantages of Monoclonal Antibodies
Monoclonal Antibodies in Oncology
Types of Monoclonal Antibodies
Chapter 4 Market Dynamics
Market Drivers
Increasing Incidence of Cancer
New Product Launches
Rising Healthcare Expenditures and Government Funding
Licensing and Collaboration Agreements
Market Barriers
Price Controls
Regulatory Approval Pressures
Entry of Biosimilars
Opportunities
Impact of COVID-19
Chapter 5 Market Breakdown by Type
Types of Monoclonal Antibodies for Oncology
Market Overview
Market Revenue
Global Market for Monoclonal Antibodies in Oncology by Type
Humanized Monoclonal Antibodies
Human Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Chapter 6 Market Breakdown by Application
Overview
Lung Cancer
Market Size and Forecast
Breast Cancer
Market Size and Forecast
Colorectal Cancer
Market Size and Forecast
Blood Cancer
Market Size and Forecast
Other Cancers
Market Size and Forecast
Chapter 7 Market Breakdown by Region
Introduction
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Rest of Asia-Pacific
Rest of the World
Market Size and Forecast
Chapter 8 Regulatory Aspects
New Approvals of Monoclonal Antibodies for Oncology
Recalls, Withdrawals, and Safety Alerts
Chapter 9 Patent Review/ New Developments
New Developments
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Chapter 10 Competitive Landscape
Mergers, Acquisitions, and Collaborations
Company Market Shares
Chapter 11 Company Profiles
AMGEN INC.
ASTRAZENECA PHARMACEUTICALS
BRISTOL-MYERS SQUIBB
ELI LILLY
F. HOFFMANN-LA ROCHE AG
GLAXOSMITHKLINE
GILEAD SCIENCES INC.
JOHNSON & JOHNSON
MERCK & CO. INC.
MERCK KGAA
PFIZER INC.
SANOFI S.A.
SEAGEN
List of Tables
Summary Table A : Global Market for Monoclonal Antibodies in Oncology, Through 2027
Summary Table B : Global Market for Monoclonal Antibodies in Oncology, by Type, Through 2027
Table 1 : Evolution of Monoclonal Antibodies
Table 2 : Advantages and Disadvantages of Monoclonal Antibodies
Table 3 : Monoclonal Antibodies Approved for Oncology
Table 4 : Murine Monoclonal Antibodies
Table 5 : Chimeric Monoclonal Antibodies
Table 6 : Humanized Monoclonal Antibodies
Table 7 : Human Monoclonal Antibodies
Table 8 : Total Number of New Cases and Deaths Due to Various Cancers Globally, 2020
Table 9 : Funding, by Research Areas, 2020
Table 10 : Global Market for Monoclonal Antibodies in Oncology, by Type, Through 2027
Table 11 : Global Market for Humanized Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 12 : Global Market for Human Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 13 : Global Market for Chimeric Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 14 : Global Market for Monoclonal Antibodies in Oncology, by Application, Through 2027
Table 15 : Global Market Market for Monoclonal Antibodies for Lung Cancer, by Region, Through 2027
Table 16 : Global Market Market for Monoclonal Antibodies for Breast Cancer, by Region, Through 2027
Table 17 : Global Market Market for Monoclonal Antibodies for Colorectal Cancer, by Region, Through 2027
Table 18 : Global Market Market for Monoclonal Antibodies for Blood Cancer, by Region, Through 2027
Table 19 : Numbers for All Cancers (Except Non-Melanoma Skin Cancer), 2020
Table 20 : Global Market for Monoclonal Antibodies for Other Types of Blood Cancer, by Region, Through 2027
Table 21 : Global Market for Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 22 : North American Market for Monoclonal Antibodies in Oncology, by Country, Through 2027
Table 23 : Cancer Incidence and Mortality, Age Standardized Rate, per 100,000, by Cancer Type, EU Countries, 2020
Table 24 : European Market for Monoclonal Antibodies in Oncology, by Country, Through 2027
Table 25 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Country, Through 2027
Table 26 : Newly Approved Monoclonal Antibodies for Oncology, 2019-April 2022
Table 27 : Recalls, Withdrawals, and Safety Alerts, 2019-April 2022
Table 28 : Monoclonal Antibodies for Oncology in Phase I Clinical Trials
Table 29 : Monoclonal Antibodies for Oncology in Phase II Clinical Trials
Table 30 : Monoclonal Antibodies for Oncology in Phase III Clinical Trials
Table 31 : M&A: Pharmaceutical Companies
Table 32 : Sales of Blockbuster Monoclonal Antibodies for Oncology, 2021
Table 33 : Amgen: Financial Performance, 2019-2021
Table 34 : AstraZeneca: Financial Performance, 2019-2021
Table 35 : AstraZeneca: Business Segment
Table 36 : Bristol-Myers Squibb: Financial Performance, 2019-2021
Table 37 : Eli Lilly: Business Segments
Table 38 : Eli Lilly: Financial Performance, 2019-2021
Table 39 : F. Hoffmann-La Roche: Business Segments
Table 40 : F. Hoffmann-La Roche: Financial Performance, 2019-2021
Table 41 : Johnson & Johnson: Business Segments
Table 42 : Johnson & Johnson: Financial Performance, 2019-2021
Table 43 : Merck & Co. Inc.: Business Segment
Table 44 : Merck & Co. Inc.: Financial Performance, 2019-2021
Table 45 : Pfizer: Business Segment
Table 46 : Pfizer: Financial Performance, 2019-2021
Table 47 : Sanofi: Business Segments
List of Figures
Summary Figure A : Global Market for Monoclonal Antibodies in Oncology, 2020-2027
Summary Figure B : Global Market for Monoclonal Antibodies in Oncology, by Type, 2020-2027
Figure 1 : Approved Antibody Therapeutics in the U.S. and EU, 2010-2021
Figure 2 : Global Estimated New Cancer Cases, by Region, 2020 vs. 2040
Figure 3 : Global Market for Monoclonal Antibodies in Oncology, by Type, 2020-2027
Figure 4 : Global Market Shares of Monoclonal Antibodies in Oncology, by Type, 2021
Figure 5 : Global Market for Humanized Monoclonal Antibodies in Oncology, by Region, 2020-2027
Figure 6 : Global Market for Human Monoclonal Antibodies in Oncology, by Region, 2020-2027
Figure 7 : Global Market for Chimeric Monoclonal Antibodies in Oncology, by Region, 2020-2027
Figure 8 : Global Market for Monoclonal Antibodies in Oncology, by Application, 2020-2027
Figure 9 : Global Market Shares of Monoclonal Antibodies in Oncology, by Application, 2021
Figure 10 : Global Market for Monoclonal Antibodies for Lung Cancer, by Region, 2020-2027
Figure 11 : Global Market for Monoclonal Antibodies for Breast Cancer, by Region, 2020-2027
Figure 12 : Global Market for Monoclonal Antibodies for Colorectal Cancer, by Region, 2020-2027
Figure 13 : Global Market for Monoclonal Antibodies for Blood Cancer, by Region, 2020-2027
Figure 14 : Global Market for Monoclonal Antibodies for Other Types of Blood Cancer, by Region, 2020-2027
Figure 15 : Global Market for Monoclonal Antibodies in Oncology, by Region, 2020-2027
Figure 16 : Global Market Shares of Monoclonal Antibodies in Oncology, by Region, 2021
Figure 17 : North American Market for Monoclonal Antibodies in Oncology, by Country, 2020-2027
Figure 18 : U.S. Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 19 : Canadian Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 20 : European Market for Monoclonal Antibodies in Oncology, by Country, 2020-2027
Figure 21 : German Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 22 : U.K. Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 23 : French Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 24 : Italian Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 25 : Spanish Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 26 : Rest of European Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 27 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Country, 2020-2027
Figure 28 : Chinese Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 29 : Indian Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 30 : Japanese Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 31 : Rest of Asia-Pacific Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 32 : Rest of the World Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 33 : Global Manufacturer/Supplier Market Shares of Monoclonal Antibodies in Oncology, 2021
Figure 34 : Amgen: Annual Revenue, 2019-2021
Figure 35 : Amgen: Total Sales Share, by Product, 2021
Figure 36 : Amgen: Total Revenue Share, by Region, 2021
Figure 37 : AstraZeneca: Annual Revenue, 2019-2021
Figure 38 : AstraZeneca: Total Sales Share, by Segment, 2021
Figure 39 : AstraZeneca: Total Revenue Share, by Region, 2021
Figure 40 : Bristol-Myers Squibb: Annual Revenue, 2019-2021
Figure 41 : Bristol Myers Squibb: Total Sales Share, by Product, 2021
Figure 42 : Bristol-Myers Squibb: Total Revenue Share, by Region, 2021
Figure 43 : Eli Lilly: Annual Revenue, 2019-2021
Figure 44 : Eli Lilly: Total Sales Share, by Product Segment, 2021
Figure 45 : Eli Lilly: Total Revenue Share, by Region, 2021
Figure 46 : F. Hoffmann-La Roche: Annual Revenue, 2019-2021
Figure 47 : F. Hoffmann-La Roche: Total Sales Share, by Pharmaceutical Segment, 2021
Figure 48 : F. Hoffmann-La Roche: Total Revenue Share, by Region, 2021
Figure 49 : Johnson & Johnson: Annual Revenue, 2019-2021
Figure 50 : Johnson & Johnson: Total Sales Share, by Business Segment, 2021
Figure 51 : Johnson & Johnson: Total Revenue Share, by Region, 2021
Figure 52 : Merck & Co. Inc.: Annual Revenue, 2019-2021
Figure 53 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2021
Figure 54 : Merck & Co. Inc.: Revenue Share, by Region, 2021
Figure 55 : Pfizer: Annual Revenue, 2019-2021
Figure 56 : Pfizer: Net Sales Share, by Business Segment, 2021
Figure 57 : Pfizer: Net Sales Share, by Region, 2021
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security